PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.5

Change

-0.10 (-2.78)%

Market Cap

N/A

Volume

0.81M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-46.00 (-4.21%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+2.99 (+0.65%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

-0.83 (-0.31%)

USD 34.90B
ARGX argenx NV ADR

-8.74 (-1.65%)

USD 32.16B
MRNA Moderna Inc

-0.20 (-0.31%)

USD 25.25B
BGNE BeiGene Ltd

+8.00 (+3.97%)

USD 22.45B
SMMT Summit Therapeutics PLC

+2.09 (+9.54%)

USD 17.92B
RPRX Royalty Pharma Plc

N/A

USD 16.34B
UTHR United Therapeutics Corporatio..

+2.28 (+0.64%)

USD 15.71B
PCVX Vaxcyte Inc

+3.54 (+3.16%)

USD 14.50B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -60.50% 20% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.50% 20% F 12% F
Trailing 12 Months  
Capital Gain -65.85% 21% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.85% 21% F 12% F
Trailing 5 Years  
Capital Gain -82.70% 38% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.70% 37% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -19.73% 30% F 17% F
Dividend Return -19.73% 30% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.94% 93% A 69% C-
Risk Adjusted Return -79.11% 16% F 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector